|
|
Volumn 171, Issue 11, 2004, Pages 1335-
|
|
Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LACTONE;
PROSTAGLANDIN SYNTHASE INHIBITOR;
ROFECOXIB;
SULFONE;
ARTICLE;
CANADA;
CARDIOVASCULAR DISEASE;
CHEMICALLY INDUCED DISORDER;
DRUG INDUSTRY;
HUMAN;
LEGAL ASPECT;
LEGAL LIABILITY;
POSTMARKETING SURVEILLANCE;
CANADA;
CARDIOVASCULAR DISEASES;
CYCLOOXYGENASE INHIBITORS;
DRUG INDUSTRY;
HUMANS;
LACTONES;
LIABILITY, LEGAL;
PRODUCT SURVEILLANCE, POSTMARKETING;
SULFONES;
|
|
EID: 16544372587
PISSN: 08203946
EISSN: None
Source Type: Journal
DOI: 10.1503/cmaj.1041692 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
